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Human infection with the nematode Strongyloides 
stercoralis is endemic in some tropical and warm areas 
of the world, including parts of Europe and the 
southeastern USA 111. The clinical presentation of 
strongyloidiasis is polymorphic, and the parasite may 
persist undetected for decades as a chronic, almost 
asymptomatic infection. Under immunosuppressive 
treatment, such as that administered after trans- 
plantation, extensive tissue invasion may develop, 
producing life-threatening systemic syndromes. 
These may be easily prevented by treating patients 
before the immunosuppression is started. Therefore, it 
is essential to evaluate transplant candidates with a 
history of residence or travel in endemic zones, to rule 
out the possibility that they harbor S. stercoralis. Never- 
theless, standard-concentration parasitologic methods 
may provide false-negative results, with the consequent 
risk of hyperinfection when immunosuppression begins. 
We describe such i case and recommend the Harada- 
Mori method for prospective screening of patients at 
risk. 
CASE REPORT 
A 47-year-old man was admitted as a candidate for 
heart transplantation because of end-stage ischemic 
heart disease. The infectious diseases specialist was 
consulted in March 1995 for evaluation of eosinophilia 
(16%; 2500/mm3) found in the initial work-up. 
The patient had lived in rural areas of Equatorial 
Guinea and Central America fkom 1979 to 1990. In 
1990 he was evacuated to Spain because of serious 
bloody diarrhea, fever and eosinophha (56%; 14 300 
eosinophils/mm3). He was then diagnosed as having 
strongyloidiasis and adult Ascaris Zumbricoides infestation, 
and was treated with three courses of thiabendazole, 
after which stool samples became negative for ova and 
parasites. No other parasites were found in stool, blood, 
skin snip biopsy or urine samples. 
He remained in Spain after the treatment. His 
physical condition deteriorated, and he was admitted 
several times to different hospitals as a result of cardio- 
vascular emergencies. Blood eosinophil counts were 
not reported to be high in any record available from this 
period of time. 
On present admission, the patient complained of 
pruritus in the trunk and lower limbs and occasional 
appearance of a single, elongated pruritic rash on the 
waist and buttocks, which faded in a few hours. He 
did not have diarrhea. Physical examination disclosed 
scratching lesions on the waist. 
Standard parasitologic studies, including examin- 
ation of blood and shn for filariae, were all negative. 
Three stool samples concentrated by the formalin-ethyl 
acetate method and a string test were exhaustively 
examined for S. stercoralis, with negative results. 
The Harada-Mori test was performed to increase 
the chances of detecting strongyloides infection. 
Approximately 6 g of freshly passed stools was smeared 
on six strips of blotting paper and placed in tubes 
containing a small amount of water. The tubes were 
incubated at 30°C in an upright position to allow the 
larvae to molt and migrate to the water. By the tenth 
day, a few filariform larvae of S.  stercoralis were detected. 
The patient received 2.5 g/day ofthiabendazole for 
5 days, with clinical and parasitologic cure. He also 
received three courses of ivermectin, even though the 
presence of Strongyloides has not been demonstrated 
again in subsequent stool samples. His follow-up has 
been unremarkable. His cardiac function is now stable, 
so heart transplantation has been postponed, but another 
course of ivermectin will eventually be provided before 
transplantation. 
DISCUSSION 
Strongyloidiasis is a widespread disease in warm, humid 
areas of the world. It is estimated that about 50 &on 
to 100 d i o n  people are infected [2]. At the present 
time, autochthonous infection in Spain is extremely 
uncommon. 
Humans usually acquire S. stercoralis infection by 
penetration of skin by the infective filariform larvae, 
usually after contact with contaminated soil. The worm 
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matures and multiplies within the human host, and may 
cause three possible clinical conditions: acute diarrhea, 
chronic silent or scarcely symptomatic gastrointestinal 
disease, and systemic infections (hyperinfection syn- 
drome and disseminated strongyloidiasis) [3]. These last 
mentioned syndromes are usually associated with sup- 
pression of the host's immune response and in the case 
of solid organ recipients, symlptoms develop in the first 
6 months post-transplantation. 
In the hyperinfection syndrome, overwhelming 
parasite load occurs, but the parasite is only found in 
the gastrointestinal and respiratory tracts. On the 
contrary, when disseminate'd strongyloidiasis occurs, 
other organs may be affected, with massive tissue inva- 
sion. Patients may present with cutaneous, gastrointest- 
inal, central nervous system or pulmonary symptoms, 
and sustained or recurrent Gram-negative bacteremia 
or meningitis may develop due to the introduction 
of bowel bacteria, either allong with penetration of 
infective larvae from the bowel or through damaged 
intestinal epithelium. Although eosinophilia is fre- 
quent, it may be absent in immunosuppressed patients. 
The mortality rate of the systemic syndromes may reach 
77%, even when thiabendazole is provided [3-51. 
The cutaneous manifestation of our patient is 
known as larva currens and occurs in association with 
autoinfection. It  is an allergic reaction to filariform 
larvae that migrate under the skin, leaving linear urti- 
carial papules. Two-thirds of individuals with chronic 
infection will develop transient and recurrent urticarial 
eruptions on the skin of the waist and buttocks. 
A high index of suspicion is required to establish 
the diagnosis, and it is essential to consider S. stercorulis 
in immunosuppressed patients with eosinophilia, recur- 
rent skin lesions, multiple pulmonary infiltrates, ileus 
with or without perforation, abdominal pain, malab- 
sorption, meningitis or bacteremia. Chronic carriage is 
common among individuals environmentally exposed 
and has been found to persist for up to 30 years [6,7]. 
In conventional fresh smear preparations for 
ova and parasites, stool samples are concentrated by 
ethylacetate-formalin centrifugation, and one drop of 
resuspended fecal material is examined under a 
microscope. In chronic disease, a few rhabditiform 
larvae are passed in feces, and in such cases conventional 
methods have low sensitivity (27% for a single stool 
examination). In some reported cases it was necessary 
to submit up to eight samples or repeat wet mount 
examinations for a cumulative time of 10 work-hours 
before parasites could be demonstrated in a given 
patient [6], and, accordingly, some authors recommend 
the administration of pre-emptive therapy to all 
transplant candidates who have traveled to or resided in 
an area of endemic infection [8].  
The Harada-Mori test-tube filter paper method 
increases the chances of recovering Strongyloides from 
intestinal samples [9]. This method utilizes the natural 
water tropism of larvae to concentrate them. A recent, 
unpreserved and unrefrigerated fecal sample is smeared 
on a strip of blotting paper. The strip is placed in a 
40-mL screw-capped tube containing a few milliters of 
water which continuously soaks the paper. The tube is 
incubated at 2428°C for up to 10 days. Strongyloides 
rhabditiform larvae migrate to the water and transform 
into filariform larvae. The water sediment is screened 
daily under a low magnification for living larvae, which 
should be differentiated from those of hookworm. This 
technique is simple, efficient, convenient, very easy to 
perform and may be requested from any clinical 
microbiology laboratory. Modifications of this method 
have been described. Among them, the Baermann 
technique uses larger volumes of feces, so increasing the 
sensitivity of the examination, which may become 
positive within hours [lo]. 
Treatment of strongyloidiasis consists of thia- 
bendazole or ivermectin. It is important to consider the 
possibility of relapses after therapy. Reported cure after 
six doses of thiabendazole (25 mg/kg per day, twice 
daily for 3 days) is 93%, but clinical or parasitologic 
failure after 6 months of follow-up may reach 33% [ 1 11. 
Ivermectin is a new antiparasitic drug developed 
primarily for veterinary medicine that has proven 
efficacious in strongyloidiasis and other infections due 
to nematodes and ectoparasites [12-141. Parasitologic 
cure was achieved in 24 out of 29 cases (83%) after a 
single dose of ivermectin (150-200 pg/kg). A recent 
comparative study indicated that ivermectin is as 
effective as thiabendazole for treating uncomplicated 
chronic strongyloidiasis and is associated with far fewer 
side effects [ 151. 
The extensive use of cyclosporin has decreased the 
risk of hyperinfection syndrome in transplantation 
recipients, as this drug has some antiparasitic effect 
[16]. However, tacrolimus does not have anthelmintic 
activity, so when it is used as an immunosuppressant, 
both donor and recipient organs must be carefully 
examined for S. stercorulis [17]. 
We want to stress the importance of considering 
this infection in the preparatory work-up for 
transplantation, and recommend the Harada-Mori 
test to increase the sensitivity of the parasitologic 
screening. 
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Small colony variants (SCVs) represent minority sub- 
populations of Staphylococcus aureus that grow slowly 
(>72 h) on routine media, yielding small, non-pig- 
mented, non-hemolytic colonies. Although S. aweus 
SCVs have been recognized for many years [l-31, the 
connection between this phenotype and persistent 
recurrent infections has only recently been appreciated. 
Clinical and laboratory-generated S. aureus SCVs are 
frequently auxotrophic for menadione or hemin, two 
compounds required in the biosynthesis of mena- 
quinone and cytochromes, components of the electron 
transport chain. The subsequent decrease in electron 
transport activity in SCVs may account for their 
resistance to a variety of antibiotics and other anti- 
staphylococcal compounds, such as protamine, some 
antibiotics, and platelet microbiocidal proteins, and also 
provide a mechanism for their persistence within host 
tissues 14-61. 
It is well known that S. aureus SCVs can be derived 
from clinical isolates both in vitro and in vivo following 
exposure to aminoglycosides and p-lactam antibiotics 
[1,2,4,5]. Mitsuyama et al. recently described the emer- 
gence of SCVs after exposure of wild-type parent 
strains to an MIC concentration of the fluoroquinolone 
pazufloxacin [7] .  Emergent SCVs were half as suscep- 
tible to pazufloxacin and ciprofloxacin as dd-type S. 
aureus. Reduced susceptibilities of SCVs to these 
compounds were not a result of mutations in gyrA, 
